Carvedilol is indicated for the treatment of mild, moderate, and severe heart failure of ischemic or cardiomyopathic origin. It is used alongside digitalis, diuretics, and ACE inhibitors to reduce disease progression, including risks of cardiovascular death, hospitalization, or the need to adjust other heart failure medications. It may also be used in patients who cannot tolerate ACE inhibitors, as well as in those not receiving digitalis, hydralazine, or nitrate therapy.

Carvedilol is a cardiovascular agent that acts primarily as a non-selective β-adrenergic receptor blocker, while also exhibiting significant α-adrenergic blocking activity. It possesses antiproliferative effects and functions as an antioxidant by scavenging reactive free radicals. It is commonly used in the management of hypertension, angina pectoris, and congestive heart failure.

Digoxin: Concomitant use with carvedilol may increase digoxin levels; monitoring of digoxin is recommended when starting, adjusting, or stopping carvedilol.

Rifampin: Pretreatment with rifampin may significantly reduce carvedilol plasma concentration (Cmax and AUC).

Warfarin: Carvedilol does not significantly affect the plasma protein binding of warfarin.

Clonidine: Beta-blockers may enhance the hypertensive response following abrupt withdrawal of clonidine; however, carvedilol’s alpha-blocking effect may reduce this response.

Carvedilol is contraindicated in patients with decompensated heart failure requiring intravenous inotropic therapy, bronchial asthma or related bronchospastic conditions, second- or third-degree AV block, sick sinus syndrome (unless a permanent pacemaker is present), cardiogenic shock, or severe bradycardia.

Adverse effects may include postural hypotension, dizziness, headache, fatigue, gastrointestinal disturbances, and bradycardia. Other effects may include reduced peripheral circulation, edema, limb pain, dry mouth, dry eyes, visual disturbances, impotence, urinary disturbances, flu-like symptoms, rare angina, AV block, worsening of claudication or Raynaud’s phenomenon, allergic skin reactions, worsening psoriasis, nasal congestion, wheezing, mood changes, sleep disturbances, paresthesia, heart failure, changes in liver enzymes, thrombocytopenia, and leukopenia.

Carvedilol is not recommended during breastfeeding, as it is excreted in breast milk. Its safety and effectiveness in children have not been established. It should also be avoided during pregnancy due to insufficient human data, although animal studies indicate that it crosses the placenta. No adequate data are available on its safety in neonates.

Caution should be exercised in patients with hepatic impairment and heart failure. Clinical status should be closely monitored for 2–3 hours after initiation of therapy and following dose increases. Before increasing the dose, ensure that renal function and heart failure status are stable and not worsening.

Alpha adrenoceptor blocking drugs, Beta-adrenoceptor blocking drugs, Beta-blockers

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.